Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania
ABSTRACT (198): Background: The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Tumour Virus Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666679021000070 |
| _version_ | 1818402619135098880 |
|---|---|
| author | K.R. Mitchell T. Erio H.S. Whitworth G. Marwerwe J. Changalucha K. Baisley C.J. Lacey R. Hayes S. de SanJosé D. Watson-Jones |
| author_facet | K.R. Mitchell T. Erio H.S. Whitworth G. Marwerwe J. Changalucha K. Baisley C.J. Lacey R. Hayes S. de SanJosé D. Watson-Jones |
| author_sort | K.R. Mitchell |
| collection | DOAJ |
| description | ABSTRACT (198): Background: The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly understood. We investigated acceptability of dose-reduction among girls, and parents/guardians of girls, randomised to receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study (DoRIS trial) in Tanzania. Methods: Semi-structured interviews with girls (n = 19), and parents/guardians of girls (n = 18), enrolled in the study and completing their vaccine course. Results: Most participants said they entrusted decisions about the number of HPV vaccine doses to experts. Random allocation to the different dose groups did not feature highly in the decision to participate in the trial. Given a hypothetical choice, girls generally said they would prefer fewer doses in order to avoid the pain of injections. Parental views were mixed, with most wanting whichever dose was most efficacious. Nonetheless, a few parents equated a higher number of doses with greater protection. Conclusion: Vaccine trials and programmes will need to employ careful messaging to explain that one dose offers sufficient protection against HPV should emerging evidence from ongoing dose-reduction clinical trials support this. |
| first_indexed | 2024-12-14T08:11:14Z |
| format | Article |
| id | doaj.art-cd1621b57d6d40338b060f6ad6f62bd8 |
| institution | Directory Open Access Journal |
| issn | 2666-6790 |
| language | English |
| last_indexed | 2024-12-14T08:11:14Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Tumour Virus Research |
| spelling | doaj.art-cd1621b57d6d40338b060f6ad6f62bd82022-12-21T23:10:04ZengElsevierTumour Virus Research2666-67902021-12-0112200217Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in TanzaniaK.R. Mitchell0T. Erio1H.S. Whitworth2G. Marwerwe3J. Changalucha4K. Baisley5C.J. Lacey6R. Hayes7S. de SanJosé8D. Watson-Jones9MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Berkeley Square, 99 Berkeley St, Glasgow, G3 7HR, UK; Corresponding author. , MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Berkeley Square, 99 Berkeley St, Glasgow G3 7HR, UK;Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, TanzaniaMwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UKMwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, TanzaniaMwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, TanzaniaFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UKYork Biomedical Research Institute & Hull York Medical School, University of York, John Hughlings Jackson Building, University Rd, Heslington, York YO10 5DD, UKFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UKCatalan Institute of Oncology, Avinguda de La Granvia de L’Hospitalet 199-203, 08908 L'Hospitalet de Llobregat (Barcelona), SpainMwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UKABSTRACT (198): Background: The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly understood. We investigated acceptability of dose-reduction among girls, and parents/guardians of girls, randomised to receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study (DoRIS trial) in Tanzania. Methods: Semi-structured interviews with girls (n = 19), and parents/guardians of girls (n = 18), enrolled in the study and completing their vaccine course. Results: Most participants said they entrusted decisions about the number of HPV vaccine doses to experts. Random allocation to the different dose groups did not feature highly in the decision to participate in the trial. Given a hypothetical choice, girls generally said they would prefer fewer doses in order to avoid the pain of injections. Parental views were mixed, with most wanting whichever dose was most efficacious. Nonetheless, a few parents equated a higher number of doses with greater protection. Conclusion: Vaccine trials and programmes will need to employ careful messaging to explain that one dose offers sufficient protection against HPV should emerging evidence from ongoing dose-reduction clinical trials support this.http://www.sciencedirect.com/science/article/pii/S2666679021000070AcceptabilityHPV vaccinationQualitativeDose reductionRandomisationTrial participation |
| spellingShingle | K.R. Mitchell T. Erio H.S. Whitworth G. Marwerwe J. Changalucha K. Baisley C.J. Lacey R. Hayes S. de SanJosé D. Watson-Jones Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania Tumour Virus Research Acceptability HPV vaccination Qualitative Dose reduction Randomisation Trial participation |
| title | Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania |
| title_full | Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania |
| title_fullStr | Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania |
| title_full_unstemmed | Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania |
| title_short | Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania |
| title_sort | does the number of doses matter a qualitative study of hpv vaccination acceptability nested in a dose reduction trial in tanzania |
| topic | Acceptability HPV vaccination Qualitative Dose reduction Randomisation Trial participation |
| url | http://www.sciencedirect.com/science/article/pii/S2666679021000070 |
| work_keys_str_mv | AT krmitchell doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT terio doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT hswhitworth doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT gmarwerwe doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT jchangalucha doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT kbaisley doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT cjlacey doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT rhayes doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT sdesanjose doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania AT dwatsonjones doesthenumberofdosesmatteraqualitativestudyofhpvvaccinationacceptabilitynestedinadosereductiontrialintanzania |